Genetic variation in DNA repair genes and prostate cancer risk: Results from a population-based study

Cancer Causes and Control

Volumn 21, Issue 2, 2010, Pages 289-300

  Agalliu, Ilir ^a   Kwon, Erika M ^b   Salinas, Claudia A ^c,d,e   Koopmeiners, Joseph S ^c,d   Ostrander, Elaine A ^b   Stanford, Janet L ^c,d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Dna repair; Genetic variation; Snps prostate cancer case control study

Indexed keywords

BRCA2 PROTEIN; DNA GLYCOSYLASE MUTY; GENE PRODUCT; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN APEX1; PROTEIN ERCC4; PROTEIN OGG1; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; BODY MASS; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DNA REPAIR; FAMILY HISTORY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HOMOZYGOSITY; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; AFRICAN AMERICANS; AGED; BRCA2 PROTEIN; CHI-SQUARE DISTRIBUTION; DNA REPAIR; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION SURVEILLANCE; PROSTATIC NEOPLASMS; RISK FACTORS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 77950689168     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-009-9461-5     Document Type: Article

References (51)

1. American Cancer Society (2009) Cancer facts and figures: 2009. American Cancer Society, Atlanta
2. 2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M et al (2000) Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl. J Med 343(2):78-85 (Pubitemid 30451850)
3. 3. Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM et al (2000) Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer. Cancer 89(1): 123-134 (Pubitemid 30451282)
4. Pathak SK, Sharma RA, Steward WP, Mellon JK, Griffiths TR, Gescher AJ (2005) Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer 41(1):61-70
5. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK (2009) Oxidative stress in prostate cancer. Cancer Lett 282(2):125-136
6. 6. Cooke MS, Evans MD, Dizdaroglu M, Lunec J (2003) Oxidative DNA damage: mechanisms, mutation, and disease. Faseb J 17( 1.0) : 1195-1214 (Pubitemid 36775767)
7. Sikka SC (2003) Role of oxidative stress response elements and antioxidants in prostate cancer pathobiology and chemoprevention-a mechanistic approach. Curr Med Chem 10(24):2679-2692
8. 8. Rybicki BA, Rundle A, Savera AT, Sankey SS, Tang D (2004) Polycyclic aromatic hydrocarbon-DNA adducts in prostate cancer. Cancer Res 64(24):8854-8859 (Pubitemid 39665489)
9. 9. Rybicki BA, Nock NL, Savera AT, Tang D, Rundle A (2006) Polycyclic aromatic hydrocarbon-DNA adduct formation in prostate carcinogenesis. Cancer Lett 239(2):157-167 (Pubitemid 43974861)
10. 10. Tang D, Liu JJ, Rundle A, Neslund-Dudas C, Savera AT, Bock CH et al (2007) Grilled meat consumption and PhIP-DNA adducts in prostate carcinogenesis. Cancer Epidemiol Biomarkers Prev 16(4):803-808 (Pubitemid 46650585)
11. 11. Christmann M, Tomicic MT, Roos WP, Kaina B (2003) Mechanisms of human DNA repair: an update. Toxicology 193(12):3-34 (Pubitemid 37340141)
12. Wood RD, Mitchell M, Sgouros J, Lindahl T (2001) Human DNA repair genes. Science 291 (5507): 1284-1289
13. Pierce AJ, Stark JM, Araujo FD, Moynahan ME, Berwick M, Jasin M (2001) Double-strand breaks and tumorigenesis. Trends Cell Biol 11:S52-S59
14. 14. Jackson SP (2002) Sensing and repairing DNA double-strand breaks. Carcinogenesis 23:687-696 (Pubitemid 34567505)
15. 15. Hu JJ, Mohrenweiser HW, Bell DA, Leadon SA, Miller MS (2002) Symposium overview: genetic polymorphisms in DNA repair and cancer risk. Toxicol Appl Pharmacol 185(1):64-73 (Pubitemid 35425698)
16. 16. Goode EL, Ulrich CM, Potter JD (2002) Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11(12):1513-1530 (Pubitemid 36020002)
17. 17. Hu JJ, Hall MC, Grossman L, Hedayati M, McCullough DL, Lohman K et al (2004) Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res 64(3): 1197-1201 (Pubitemid 38176929)
18. 18. Hung RJ, Hall J, Brennan P, Boffetta P (2005) Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am J Epidemiol 162(10):925-942 (Pubitemid 41619464)
19. 19. Xu J, Zheng SL, Turner A, Isaacs SD, Wiley KE, Hawkins GA et al (2002) Associations between. hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 62(8):2253-2257 (Pubitemid 34411700)
20. van Gils CH, Bostick RM, Stern MC, Taylor JA (2002) Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene. Cancer Epidemiol Biomarkers Prev 11(11):1279-1284
21. 21. Rybicki BA, Conti DV, Moreira A, Cicek M, Casey G, Witte JS (2004) DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 13(1):23-29 (Pubitemid 38116616)
22. 22. Ritchey JD, Huang WY, Chokkalingam AP, Gao YT, Deng J, Levine P et al (2005) Genetic variants of DNA repair genes and prostate cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 1.4(7): 1.703-1.709 (Pubitemid 40995083)
23. 23. Nock NL, Cicek MS, Li L, Liu X, Rybicki BA, Moreira A et al (2006) Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 27(9):1842-1848 (Pubitemid 44288666)
24. 24. Chen L, Ambrosone CB, Lee J, Sellers TA, Pow-Sang J, Park JY (2006) Association between polymorphisms in the DNA repair genes XRCCl and APEl, and the risk of prostate cancer in white and black Americans. J Urol 175(1):108-112 (discussion 12) (Pubitemid 41797104)
25. 25. Hirata H, Hinoda Y, Tanaka Y, Okayama N, Suehiro Y, Kawamoto K et al (2007) Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer 43(2):231-237 (Pubitemid 46123995)
26. Hooker S, Bonilla C, Akereyeni F, Ahaghotu C, Kittles RA (2008) NAT2 and NER genetic variants and sporadic prostate cancer susceptibility in African Americans. Prostate Cancer Prostatic Dis 11(4):349-356
27. Stanford JL, Wicklund KG, McKnight B, Daling JR, Brawer MK (1999) Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 8(10):881-886
28. 28. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL (2008) Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 168(3):250-260 (Pubitemid 352019786)
29. Sunyaev S, Ramensky V, Koch I, Lathe W 3rd, Kondrashov AS, Bork P (2001) Prediction of deleterious human alleles. Hum Mol Genet 10(6):591-597
30. Sambrook J, Fritsch EF, Maniatis T (1989) Isolation of highmolecular weight DNA from mammalian cells. In: Nolan C (ed) Molecular cloning: a laboratory manual. Cold Spring Harbor Press, Plainview, pp 9.16-99.9
31. Ott J (1999) Analysis of human genetic linkage. John Hopkins University Press, Baltimore
32. Breslow NE, Day NE (1980) Statistical methods in cancer research, volume 1-the analysis of case-control studies. International Agency for Research on Cancer, Lyon
33. Klienbaum DG, Nizam A, Kupper L, Muller KE (2007) Applied regression analysis and multivariate methods, 4th edn. Duxbury Press, Pacific Grove
34. 34. Dubin N, Pasternack BS (1986) Risk assessment for case-control subgroups by polychotomous logistic regression. Am J Epidemiol 123(6):1101-1117 (Pubitemid 16039954)
35. The Breast Cancer Linkage C (1.999) Cancer risks in BRCA.2 mutation carriers. J Natl Cancer Inst 91(15): 1310-1316
36. 36. Johannsson O, Loman N, Moller T, Kristoffersson U, Borg A, Olsson H (1999) Incidence of malignant tumours in relatives of BRCAl and BRCA2 germline mutation carriers. Eur J Cancer 35(8): 1248-1257 (Pubitemid 29359186)
37. 37. Eerola H, Pukkala E, Pyrhonen S, Blomqvist C, Sankila R, Nevanlinna H (2001) Risk of cancer in BRCAl and BRCA2 mutation-positive and -negative breast cancer families (Finland). Cancer Causes Control 12:739-746 (Pubitemid 32803500)
38. 38. Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir RB, Egilsson V et al (2002) The effect of a single BRCA2 mutation on cancer in Iceland. J Med Genet 39(7):457-462 (Pubitemid 34787737)
39. Bermejo JL, Hemminki K (2004) Risk of cancer at sites other than the breast in Swedish families eligible for BRCAl or BRCA2 mutation testing. Ann Oncol 15:1834-1841
40. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S (2005) Cancer risks in BRC.A2 families: estimates for sites other than breast and ovary, J Med Genet 42:711-719
41. 41. Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjörd JE et al (1997) BRCA2 mutation in Icelandic prostate cancer patients. J Mol. Med 75:758-761 (Pubitemid 27451978)
42. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M et al (1.997) The risk of cancer associated with specific mutations of BRCAl and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20): 1401-1408
43. 43. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C et al (2004) BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10:2918-2921 (Pubitemid 38619665)
44. Agalliu I, Gern R, Leanza S, Burk RD (2009) Associations of high-grade prostate cancer with BRCAl and BRCA2 founder mutations. Clin Cancer Res 15(3):1112-1120
45. 45. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P et al (2003) Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1-12 (Pubitemid 36056838)
46. 46. Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A, Ostrander EA et al (2007) Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 97(6):826-831 (Pubitemid 47396283)
47. Ostrander EA, Udler MS (2008) The role of the BRCA2 gene in susceptibility to prostate cancer revisited. Cancer Epidemiol Biomarkers Prev 17(8):1.843-1.848
48. 48. Braithwaite E, Wu X, Wang Z (1998) Repair of DNA lesions induced by polycyclic aromatic hydrocarbons in human cell-free extracts: involvement of two excision repair mechanisms in vitro. Carcinogenesis 1.9(7): 1239-1246 (Pubitemid 28375374)
49. Platz EA, De Marzo AM, Giovannucci E (2004) Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era. J Cell Biochem 91(3):553-571
50. 50. Kondylis FI, Moriarty RP, Bostwick D, Schellhammer PF (2003) Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias. J Urol 170(4 Pt 1):1189-1193 (Pubitemid 37108110)
51. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PDH (2005) Prostate cancer and the Will Rogers phenomenon. J Natl. Cancer Inst 97(1.7): 1.248-1.252